| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP2K7 |
| Uniprot No | O14733 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-419aa |
| 氨基酸序列 | AASSLEQKL SRLEAKLKQE NREARRRIDL NLDISPQRPR PTLQLPLAND GGSRSPSSES SPQHPTPPAR PRHMLGLPST LFTPRSMESI EIDQKLQEIM KQTGYLTIGG QRYQAEINDL ENLGEMGSGT CGQVWKMRFR KTGHVIAVKQ MRRSGNKEEN KRILMDLDVV LKSHDCPYIV QCFGTFITNT DVFIAMELMG TCAEKLKKRM QGPIPERILG KMTVAIVKAL YYLKEKHGVI HRDVKPSNIL LDERGQIKLC DFGISGRLVD SKAKTRSAGC AAYMAPERID PPDPTKPDYD IRADVWSLGI SLVELATGQF PYKNCKTDFE VLTKVLQEEP PLLPGHMGFS GDFQSFVKDC LTKDHRKRPK YNKLLEHSFI KRYETLEVDV ASWFKDVMAK TESPRTSGVL SQPHLPFFR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP2K7重组蛋白的3篇代表性文献摘要(内容为虚构示例，仅供参考)：
1. **文献名称**: *"Recombinant Expression and Functional Characterization of Human MAP2K7 in Escherichia coli"*
**作者**: Zhang Y, et al.
**摘要**: 本研究成功构建了人源MAP2K7的重组表达载体，并利用大肠杆菌系统实现高效表达。通过亲和层析纯化获得高纯度蛋白，体外激酶实验证实其可磷酸化下游JNK蛋白，验证了重组MAP2K7的生物学活性。
2. **文献名称**: *"Structural Insights into MAP2K7 Activation Mechanism by X-ray Crystallography"*
**作者**: Thompson R, et al.
**摘要**: 通过X射线晶体学解析了重组MAP2K7蛋白的激活态三维结构，揭示了其与MEK家族激酶相似的激酶结构域特征，并发现磷酸化位点对其构象变化的关键作用，为靶向药物设计提供了结构基础。
3. **文献名称**: *"MAP2K7 Knockdown Attenuates TNF-α-Induced Apoptosis via JNK Pathway Modulation"*
**作者**: Lee S, et al.
**摘要**: 利用重组MAP2K7蛋白进行体外激酶抑制实验，发现其介导的JNK信号通路在TNF-α诱导的细胞凋亡中起核心作用。研究为炎症相关疾病治疗提供了潜在靶点。
(注：以上文献信息为示例，实际文献需通过PubMed或Google Scholar等平台检索。)
**Background of MAP2K7 Recombinant Protein**
MAP2K7 (mitogen-activated protein kinase kinase 7), also known as MEK7. is a dual-specificity kinase within the MAPK signaling pathway. It functions as a critical upstream activator of the c-Jun N-terminal kinase (JNK) pathway, which regulates cellular responses to stress, apoptosis, inflammation, and differentiation. Structurally, MAP2K7 contains a conserved kinase domain and phosphorylation sites essential for its activation by MAP3Ks (e.g., ASK1. MLK3). Upon stimulation by cytokines, growth factors, or environmental stressors, MAP2K7 phosphorylates JNK, triggering downstream effects on transcription factors like c-Jun.
Recombinant MAP2K7 protein is produced via genetic engineering in heterologous systems (e.g., *E. coli*, mammalian cells*) to study its biochemical properties, interactions, and role in signaling cascades. This purified protein retains enzymatic activity, enabling *in vitro* kinase assays, structural studies, and drug discovery efforts. Its applications span elucidating JNK pathway mechanisms, modeling diseases linked to MAP2K7 dysregulation (e.g., cancer, neurodegenerative disorders), and screening therapeutic inhibitors.
MAP2K7 mutations or aberrant expression are implicated in pathologies such as inflammation-driven cancers, autoimmune diseases, and tissue damage. Research using recombinant MAP2K7 aids in understanding its regulatory networks and developing targeted therapies. The protein’s stability, specificity, and compatibility with high-throughput platforms make it a vital tool for both basic and translational research in cellular signaling.
×
